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PInsulin Resistance, Platelets, and Obesity
nsulin Resistance as a Determinant
f Platelet Activation in Obese Women
tefania Basili, MD,‡ Giovanni Pacini, DSC,† Maria Teresa Guagnano, MD,*
aria Rosaria Manigrasso, MD,* Francesca Santilli, MD,* Caterina Pettinella, BS,*
iovanni Ciabattoni, MD,* Carlo Patrono, MD,§ Giovanni Davì, MD*
hieti, Padova, and Rome, Italy
OBJECTIVES We tested the hypothesis that insulin resistance, per se, contributes to increased platelet
activation in obesity, independently of underlying inflammation.
BACKGROUND Obesity, insulin resistance, and atherosclerosis are closely linked phenomena associated with
low-grade inflammation. Obesity is associated with persistent platelet activation in otherwise
healthy women.
METHODS We performed a cross-sectional study in 40 obese and 20 non-obese healthy women using
urinary thromboxane metabolite excretion as a non-invasive index of platelet activation. An
index of insulin sensitivity, SI, and plasma adiponectin, C-reactive protein (CRP), and CD40
ligand (CD40L) levels were measured.
RESULTS Obese women had significantly (p  0.0001) higher 11-dehydro-thromboxane B2 (11-
dehydro-TXB2) excretion (median 718 vs. 211 pg/mg creatinine), CRP (1.13 vs. 0.48 mg/l),
and CD40L levels (4.45 vs. 0.90 ng/ml) than controls. Obese women had lower SI (median
2.51 vs. 5.0 104 min1/[U/ml], p  0.002) and adiponectin (6.3 vs. 10 g/ml, p  0.01)
than control subjects. On multiple regression analysis, waist-to-hip ratio ( 0.27, p 0.05)
and SI (  0.72, p  0.04) predicted 11-dehydro-TXB2 excretion rate, independently of
adiponectin, CRP, CD40L, and lipid patterns. In order to investigate the cause-effect
relationship of these associations, we examined the effects of a 12-week weight loss program
or a 3-week pioglitazone treatment on urinary 11-dehydro-TXB2 in 10 women with impaired
SI and visceral obesity. Successful weight loss (0.6 kg loss/week) achieved in 5 subjects was
associated with increased SI (92%) and decreased CD40L (27%), CRP (37%), and
11-dehydro-TXB2 (53%) (p  0.05). Consistently, improvement of insulin sensitivity
achieved with pioglitazone significantly decreased urinary 11-dehydro-TXB2 excretion
(43%, p  0.05) without changes in body weight.
CONCLUSIONS Insulin resistance is a major determinant of platelet activation in female obesity. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.040Cardiol 2006;48:2531–8) © 2006 by the American College of Cardiology Foundation
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bbesity, insulin resistance, and atherosclerosis are closely
inked phenomena, often associated with low-grade inflam-
ation (1). It has been suggested that insulin resistance or
ts associated hyperinsulinemia are independent risk factors
or coronary artery disease, with a level of risk similar to that
f hyperlipidemia (2,3). Coronary artery disease has been
elated to chronic, subclinical inflammation, as indicated by
levated circulating levels of inflammatory proteins (4).
roinflammatory proteins have been related to insulin
esistance cross sectionally (5–7).
Obesity is associated with insulin resistance (8). Although
isceral obesity is much more strongly linked to insulin resis-
ance, this relation is not present in all obese individuals (8).
From the Center of Excellence on Aging and Departments of Medicine and Drug
ciences, University of Chieti “G. D’Annunzio” Schools of Medicine and Pharmacy,
hieti, Italy; †Metabolic Unit, Institute of Biomedical Engineering, National
esearch Council, Padova, Italy; and the Departments of ‡Medical Therapy and
Pharmacology, University of Rome “La Sapienza,” Rome, Italy. This research was
upported by the European Commission FP6 funding (LSHM-CT-2004-005033)
nd also by the Italian Ministry of University and Research (FIRB RBNE01A882_004).N
Manuscript received May 15, 2006; revised manuscript received August 2, 2006,
ccepted August 7, 2006.We previously reported that visceral obesity is associated
ith enhanced lipid peroxidation and persistent platelet
ctivation in otherwise healthy women (9). This abnormal-
ty appeared to be driven by inflammatory triggers that were,
t least in part, down-regulated after a successful weight-
oss program (9). The finding that human platelets have
nsulin receptors that participate in the regulation of platelet
unction (10) led to the hypothesis that platelets are poten-
ial sites of insulin resistance, and that the latter is associated
ith impairment in the physiological antiaggregating action
xerted by insulin (11). In the present report, we tested the
ypothesis that insulin resistance, per se, contributes to
ncreased platelet activation in obesity, independently of
nderlying inflammation.
ETHODS
orty non-diabetic obese women (age 24 to 63 years) were
tudied on an outpatient basis as a follow-up investigation of
ardiovascular risk evaluation. Subjects had to be in good
eneral health and physical condition and had to have a
ody mass index (BMI)30 kg/m2 at the time of screening.
one had a family history of premature cardiovascular
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Insulin Resistance and Platelet Activation in Obesity December 19, 2006:2531–8isease or a personal history of thyroid or pituitary disease,
norexia, or bulimia. To avoid confounding by other deter-
inants of platelet activation, women were excluded if they
ad a history or evidence of atherothrombotic diseases,
iabetes mellitus, cigarette smoking, dyslipidemia, or arte-
ial hypertension. Women were also excluded if they were
regnant; had given birth in the previous 6 months; or were
aking hormonal contraception or replacement therapy,
ow-dose aspirin, non-steroidal anti-inflammatory drugs, or
itamin supplements. Three women were post-menopausal.
standard 75-g oral glucose tolerance test (OGTT) was
erformed, and glucose tolerance status was based on the
orld Health Organization criteria (12). Twenty healthy
omen (BMI 25 kg/m2), age 24 to 49 years, were also
ecruited as a control group. All women were recruited at
he Eating Disorders Clinic of the University of Chieti,
fter they were interviewed and agreed to participate in an
utpatient study. Their characteristics are detailed in Table
. All subjects gave written informed consent, and the study
rotocol was approved by the institutional review board.
nthropometric measurements. Anthropometric mea-
urements were taken according to standardized procedures.
Table 1. Clinical and Laboratory Parameters in
Parameters
No
Age (yrs)
Body mass index (kg/m2)
Waist-to-hip ratio
Total cholesterol (mmol/l)
Triglycerides (mmol/l)
HDL-C (mmol/l)
SI (10
4 min1/[U/ml])* 5.
AIRG (U/ml)* 23
Disp index (102 min1)* 1.
Adiponectin (g/ml) 10
C-reactive protein (mg/l) 0.
CD40L (ng/ml) 0.
U-11-dehydro-TXB2 (pg/mg creatinine) 2
Data are expressed as mean  SD or median (interquartile
sampled intravenous glucose tolerance test; insulin-sensitivi
index (SI  AIRG)
Abbreviations and Acronyms
11-dehydro-TXB2  11-dehydro-thromboxane B2
AUC  area under the response curve
BMI  body mass index
CD40L  CD40 ligand
CRP  C-reactive protein
DI  disposition index
FSIGT  insulin-modified frequently
sampled intravenous glucose
tolerance test
OGIS  oral glucose insulin sensitivity
OGTT  oral glucose tolerance test
SI  insulin sensitivity index
WHR  waist-to-hip ratio
AIRG  incremental acute insulin response11-dehydro-TXB2  11-dehydro-thromboxane B2; CD40L
cholesterol; U  urinary.eight, weight, and waist and hip circumferences were
easured while the subjects wore indoor clothes without
hoes. Body mass index and waist-to-hip ratio (WHR) were
omputed. The WHR was defined as the minimal abdom-
nal circumference between the xiphoid process and the iliac
rests (waist) divided by the circumference determined over
he femoral heads (hip). The cut-off point used to distin-
uish between android and gynoid fat distribution was 0.86
android type, 0.86; gynoid type, 0.86). Fat mass (kg)
as determined using bioelectrical impedance analysis
B.I.A.101-F-Akern System SRL, Florence, Italy).
esign of the studies. In the first study, we performed a
ross-sectional comparison of urinary 11-dehydro-
hromboxane B2 (11-dehydro-TXB2), a major enzymatic
etabolite of thromboxane A2 (13), insulin sensitivity (SI),
lasma adiponectin, C-reactive protein (CRP), and CD40
igand (CD40L) levels, in the 2 groups of women.
In order to investigate the cause-effect relationship of asso-
iations characterized in the cross-sectional study, we examined
he effects of a short-term weight loss program on urinary
1-dehydro-TXB2 in 10 of the 20 obese women with impaired
I (2.5 10
4 min1/[U/ml]), who agreed to participate in
his additional study. This involved a caloric restriction to
bout 1,200 kcal/day in order to achieve approximately 0.6 kg
oss/week, during a 12-week period. Successful weight loss was
efined as a reduction of at least 5 kg of the initial body weight.
efore and after the weight loss program, participants were
nstructed to perform an overnight urine collection and had a
asting blood sample drawn the following morning. Plasma,
erum, and urine were stored in aliquots at 20°C until used
or the various analyses.
Finally, to further investigate the relationship between in-
ulin resistance and platelet activation and to avoid confound-
ng by weight loss, we performed a single-blind, placebo-
ontrolled 3-week study with pioglitazone, 30 mg daily (Actos,
akeda Ireland Limited, Kilruddery, Ireland), a peroxisome
roliferator-activated receptor- ligand that acts as an insulin-
nobese and Obese Women
e Women
20)
Obese Women
(n  40) p Value
 7 41  10 0.1048
 2 38  6 0.0001
 0.06 0.91  0.10 0.0001
 0.51 4.8  0.72 0.0179
 0.41 1.19  0.62 0.0239
 0.23 1.37  0.36 0.8577
82–8.03) 2.51 (1.73–4.99) 0.0023
.0–34.3) 41.8 (21.7–72.0) 0.0079
72–1.89) 0.97 (0.53–1.90) 0.6991
8–12.5) 6.3 (4.6–10.5) 0.0121
29–0.57) 1.13 (0.67–2.13) 0.0001
60–1.35) 4.45 (2.1–6.5) 0.0001
5–300) 718 (522–1,280) 0.0001
). *Metabolic parameters from insulin-modified frequently
x (SI), incremental acute insulin response (AIRG), DispNo
nobes
(n 
37
23
0.80
4.37
0.83
1.37
00 (3.
.7 (10
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December 19, 2006:2531–8 Insulin Resistance and Platelet Activation in Obesityensitizing agent (14). During this period, the 5 obese women
ho failed to achieve successful weight loss after 12 weeks of
aloric restriction were allocated to pioglitazone (30 mg/day),
hereas the 5 obese women with impaired SI, who did not
articipate in the weight loss program, received placebo. Before
nd after the intervention, participants were instructed to
erform an overnight urine collection and had a fasting blood
ample drawn the following morning. Moreover, a standard
5-g OGTT was performed after a 10-h overnight fast at
aseline and at the end of the 3-week treatment period.
ssessment of insulin sensitivity. Insulin sensitivity was
ssessed using insulin-modified frequently sampled intrave-
ous glucose tolerance test (FSIGT) for the cross-sectional
nd weight loss studies. All studies were performed in the
ecumbent position beginning at 8 AM, after a 10- to 12-h
vernight fast. A Teflon catheter was inserted into a
eripheral vein in each forearm for blood sampling and for
lucose and insulin administration, respectively. Basal blood
amples were collected at time 10 and 1 min, after
hich glucose (300 mg/kg body weight) was infused intra-
enously within 30 s, starting at time 0. At time 20 min,
apid insulin (0.03 IU/kg, Humulin R, Eli Lilly, Indianap-
lis, Indiana) was infused for 5 min. The sampling schedule
as 2, 4, 8, 19, 27, 30, 40, 50, 70, 100, and 180 min
ccording to Steil et al. (15) with slight modifications.
For the pioglitazone intervention study, insulin sensitivity
as evaluated using 75-g 2-h OGTT values. Plasma sam-
les were obtained at 0, 30, 60, 90, and 120 min after
lucose loading.
nalytical measurements. Blood glucose was measured by
he glucose-oxidase method, plasma insulin was measured
y radioimmunoassay (Coat-A-Count Insulin Kit, Diag-
ostic Products Corporation, Los Angeles, California).
otal cholesterol, triglycerides, high-density lipoprotein
holesterol, and low-density lipoprotein cholesterol concen-
rations were determined as previously described (9).
Plasma CD40L was determined by enzyme-linked im-
unoadsorbent assay (R&D Systems, Minneapolis, Min-
esota). Plasma CRP levels were measured with a highly
ensitive immunoassay (16). Plasma adiponectin levels were
easured by enzyme-linked immunoadsorbent assay (R&D
ystems). Inter-assay and intra-assay variations of all mea-
urements were 10%. Urinary 11-dehydro-TXB2 was
easured by a previously described and validated radioim-
unoassay method (17).
ata analysis and statistics. Glucose and insulin concen-
rations obtained by FSIGT were analyzed using the min-
mal model method (18) that provides an index of insulin
ensitivity (SI) (i.e., the effect of insulin on glucose uptake
19] by taking into account glucose disposal in the tissues
nd net hepatic balance).
Insulin secretion was evaluated as the incremental acute
nsulin response, AIRG, calculated by averaging insulin
oncentrations above basal from 3 to 10 min after glucose
njection. Plasma insulin clearance was calculated as the
atio of insulin dose to dynamic area under the insulin eoncentration curve from 20 to 180 min (20). SI 
AIRG/100 gives the disposition index (DI), a measure of
he combined effect of insulin secretion and sensitivity on
lucose disposal (21,22).
The plasma glucose response and total insulin secretion
btained by OGTT were evaluated from the area under the
esponse curve (AUC) for plasma glucose and insulin (2-h
lucose AUC and 2-h insulin AUC), calculated from the
asting, 30-, 60-, 90-, and 120-min plasma concentrations
sing the trapezoid rule. The oral glucose insulin sensitivity
OGIS) index, proposed by Mari et al. (23), was calculated
s previously described. The parameters obtained by the
ifferent methods used in the 2 intervention studies (SI and
GIS) have been previously shown to be significantly
orrelated (24).
The data were analyzed by non-parametric methods to
void assumptions about the distribution of the measured
ariables. Comparisons between groups were made with the
ruskal-Wallis method and Mann-Whitney U test. The
ssociation between different measurements was assessed by
he Spearman rank correlation test. Multiple linear regres-
ion analysis was conducted to assess independent predictors
f 11-dehydro-TXB2 levels. The differences between base-
ine and post-treatment values were analyzed with the
ilcoxon signed rank test. All values are reported as mean
SD or median (interquartile range). A p value lower than
.05 was regarded as statistically significant. All tests were
-tailed, and analyses were performed using a computer
oftware package (Statistica version 6, StatSoft Inc., Tulsa,
klahoma or Statistical Package for the Social Sciences,
ersion 13.0, SPSS Inc., Chicago, Illinois).
ESULTS
linical and laboratory parameters of the non-obese and
bese women are detailed in Table 1. Obese women had
igher BMI, WHR, total cholesterol, and triglyceride
erum levels than control subjects. By contrast, SI was lower
nd AIRG was higher indicating insulin resistance and
yperinsulinemia in obese women. Plasma adiponectin was
ower in obese women and significantly correlated with SI
Rs  0.83, p  0.0001) and DI (Rs  0.48, p  0.0017).
Consistent with our earlier findings (9), obese women
ad markedly higher urinary 11-dehydro-TXB2 excretion
ate, an index of in vivo platelet activation, when compared
ith non-obese controls (Table 1). Plasma CD40L and
RP levels were also significantly higher in obese than in
on-obese women (Table 1). As shown in Table 2, a
tatistically significant direct correlation was found between
rinary 11-dehydro-TXB2 excretion rate and WHR,
D40L or CRP, and a significant inverse correlation
etween 11-dehydro-TXB2 and SI, plasma adiponectin or
I. No significant correlation was observed between urinary
1-dehydro-TXB2 and AIRG.
When the association between urinary 11-dehydro-TXB2xcretion and SI was investigated in non-obese women, a
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Insulin Resistance and Platelet Activation in Obesity December 19, 2006:2531–8ignificant inverse correlation was also observed (Rs 
0.62, p  0.006).
To further define the relationship between 11-dehydro-
XB2, anthropometric measurements (WHR, BMI), met-
bolic variables (SI, DI, serum cholesterol, triglycerides),
lasma adiponectin, CD40L and CRP, a multiple regres-
ion analysis was performed with 11-dehydro-TXB2 as the
ependent variable. This analysis yielded a model in which
I (  0.72, SEM  0.32, p  0.04) and WHR ( 
.27, SEM  0.13, p  0.05) independently predicted
rinary 11-dehydro-TXB2 excretion rate.
Therefore, we stratified obese women on the basis of
hese 2 parameters. Using a SI value of 2.5 10
4 min1/(U/
l), corresponding to the median value of obese women, we
eparated subjects with normal (4.99 [3.82 to 7.0] 104
in1/[U/ml], median [interquartile range], n  20) or
mpaired (1.73 [1.21 to 2.05] 104 min1/[U/ml], n  20)
I. Using a WHR value of 0.86, we characterized women
ith gynoid or android obesity.
Figure 1 shows the excretion rate of 11-dehydro-TXB2
n gynoid obesity (n  15) and in android obesity (n 
5) according to SI categorization. In android obesity,
mpaired SI discriminated women with significantly
igher urinary excretion of 11-dehydro-TXB2 (p 
.0033). In addition, women with android obesity and
mpaired SI showed higher plasma levels of CRP (1.98
1.20 to 2.56] vs. 0.81 [0.60 to 1.10] mg/l, p  0.0008)
nd CD40L (8.2 [5.1 to 8.9] vs. 3.2 [2.3 to 5.2] ng/ml,
 0.006) compared with women with android obesity
ut normal insulin sensitivity.
To characterize the cause-and-effect relationship of these
ssociations, we examined the effects of a 3-month weight
oss program, by assessing changes associated with caloric
estriction in 10 of the 15 android obese women with
mpaired SI (2.5 10
4 min1/[U/ml]). Successful weight
oss (108.7  13.2 to 93.2  6.8 kg; median reduction:
able 2. Spearman’s Correlation Coefficients Among the Various
CD40L CRP BMI
-11-dehydro-TXB2 0.66 0.67 0.20
p  0.0001 p  0.0001 p  0.206
D40L — 0.55 0.26
p  0.0003 p  0.109
RP — — 0.11
p  0.489
MI — — —
HR — — —
diponectin — — —
AIRG — — —
I index — — —
AIRG  incremental acute insulin response; BMI  body mass index; CD40L 
ndex; U-11-dehydro-TXB2  urinary 11-dehydro-thromboxane B2; WHR  wais9.5%) was achieved in 5 subjects and was associated with
s
2statistically significant increase in SI (92%, p  0.05)
nd decreases in plasma CD40L (27%, p  0.05) and
RP (37%, p  0.05) as well as in urinary 11-dehydro-
XB2 excretion (53%, p  0.05) (Fig. 2). In the other 5
bese women, the weight loss program failed (101.8 
5.74 to 101.4  14.4 kg; median: 1%), and the urinary
1-dehydro-TXB2 excretion decreased non-significantly by
5% (697 [638 to 797] vs. 595 [525 to 705] pg/mg
reatinine, p  0.05) (Fig. 2), in association with substan-
ially unaltered SI levels (from 2.0 [1.7 to 2.06] to 2.0 [1.5
o 2.0] 104 min1/[U/ml], p  0.05).
In the 10 patients undergoing the weight loss program, a
tatistically significant direct correlation was observed when
meters Analyzed in 40 Obese Women
HR Adiponectin AIRG DI SI
32 0.56 0.16 0.37 0.72
0.043 p  0.0002 p  0.315 p  0.017 p  0.0001
21 0.47 0.41 0.18 0.73
0.188 p  0.003 p  0.0085 p  0.257 p  0.0001
16 0.64 0.09 0.39 0.65
0.326 p  0.0001 p  0.555 p  0.012 p  0.0001
55 0.02 0.19 0.11 0.02
.0003 p  0.874 p  0.240 p  0.487 p  0.904
0.03 0.01 0.01 0.04
p  0.837 p  0.964 p  0.937 p  0.799
— 0.016 0.48 0.83
p  0.316 p  0.002 p  0.0001
— — 0.64 0.28
p  0.0001 p  0.0833
— — — 0.50
p  0.001
ligand; CRP  C-reactive protein; DI  disposition index; SI  insulin-sensitivity
p ratio.
igure 1. Urinary 11-dehydro-thromboxane B2 (11-dehydro-TXB2) ex-
retion in obese women. Urinary 11-dehydro-TXB2 excretion in android
besity (waist-to-hip ratio 0.86, n  25) and in gynoid obesity (waist-
o-hip ratio 0.86, n  15) according to normal or impaired insulinPara
W
0.
p 
0.
p 
0.
p 
0.
p  0
—
—
—
—ensitivity (insulin sensitivity index [SI] above or below the median value of
.5 104 min1/[U/ml]).
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December 19, 2006:2531–8 Insulin Resistance and Platelet Activation in Obesityelating changes in body weight to changes in urinary
1-dehydro-TXB2 excretion (Rs  0.71, p  0.03), plasma
D40L (Rs  0.66, p  0.04) and CRP (Rs  0.75, p 
.02). An inverse correlation was found when relating
hanges in body weight to changes in SI (Rs  0.77, p 
.01).
Because the concurrent weight loss may confound the
nterpretation of the reduction in platelet activation, a
hort-term treatment with pioglitazone (30 mg daily for 3
eeks) was carried out in the 5 obese women in whom the
eight loss program failed, whereas the 5 obese women with
mpaired SI who did not participate in the weight loss
rogram were allocated to a short-term placebo treatment as
control group. This single-blind placebo-controlled study
emonstrated that pioglitazone treatment was associated
ith an improvement in insulin sensitivity (OGIS 446 [444
o 471] vs. 490 [481 to 505] mg/min/m2, p  0.04) and
ith significantly decreased urinary 11-dehydro-TXB2 ex-
retion (891 [629 to 974] vs. 469 [438 to 550] pg/mg
reatinine, p  0.05) (Fig. 2) and plasma CD40L (1.79
1.60 to 1.89] vs. 1.20 [1.13 to 1.36] ng/ml, p  0.011).
lacebo was not associated with any statistically significant
hanges (OGIS 547 [492 to 561] vs. 546 [491 to 562]
g/min/m2, p  NS; 11-dehydro-TXB2 658 [439 to 699]
s. 851 [556 to 936] pg/mg creatinine, p 0.05; and plasma
D40L 1.80 [1.59 to 1.81] vs. 1.66 [1.62 to 1.76] ng/ml,
 0.05). No statistically significant changes in body
igure 2. Effects of weight loss or pioglitazone on urinary 11-dehydro-
reatment on urinary 11-dehydro-TXB2 excretion in android obese women
xcretion rates are represented for 15 women participating in the 2 studieeight (98.8  8.9 kg to 97.6  8.5 kg in the pioglitazone iroup vs. 95.1  11.2 kg to 93.6  11.1 kg in the placebo
roup), CRP levels, or serum lipids (data not shown) were
bserved in either group.
ISCUSSION
evere overweight and particularly visceral obesity is asso-
iated with increased morbidity and mortality (25) through
variety of molecular mechanisms linking the metabolic
yndrome to hemostatic and vascular abnormalities (26).
besity is associated with impaired insulin signalling, and
ntra-abdominal fat deposition is highly related to insulin
esistance (8). However, the association of obesity and
nsulin resistance is not necessarily present in all obese
ubjects, and nonobese, nondiabetic individuals may be
nsulin resistant (27).
We have previously characterized a novel mechanism
hrough which visceral obesity may affect cardiovascular
orbidity and mortality in women (i.e., thromboxane-
ependent platelet activation) (9). Biochemical evidence of
ncreased platelet activation in vivo was obtained through
on-invasive measurements of thromboxane metabolite ex-
retion (13) that avoid artifactual platelet activation during
nd after blood sampling (28).
The abnormal metabolic state that accompanies insulin
esistance renders arteries susceptible to atherosclerosis, by
ltering the functional properties of multiple cell types,
boxane B2 (11-dehydro-TXB2). Effects of weight loss or pioglitazone
impaired insulin sensitivity. Mean  SD percentage of baseline metabolite
e p values were assessed by Wilcoxon signed rank test.thromncluding platelets (29). In vitro and in vivo studies show
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Insulin Resistance and Platelet Activation in Obesity December 19, 2006:2531–8hat insulin inhibits platelet aggregation in healthy non-
bese subjects, an effect that is blunted in obese individuals
30), raising the possibility that platelets, which exhibit
nsulin receptors, may be sites of insulin resistance (11).
hus, an impaired platelet response to insulin could be
nother feature of the insulin resistance syndrome.
In the present study, we tested the hypothesis that
hromboxane-dependent platelet activation in obesity is
elated to insulin resistance, per se, independently of vascu-
ar inflammation or adypocyte-derived adipokines associ-
ted with insulin resistance. Because comorbidity associated
ith the obese state might confound the association with
latelet activation, we selected a group of obese women free
f other cardiovascular risk factors previously associated
ith persistent platelet activation (31–33). Our results in
bese women without abnormal fasting glucose or impaired
lucose tolerance demonstrate that thromboxane-dependent
latelet activation is related to insulin sensitivity and not to
mpaired insulin secretion, because SI, but not AIRG,
ndependently predicted thromboxane metabolite excretion.
There is a large body of evidence that insulin secretion
nd insulin sensitivity are strictly related (22). It has been
nown since the 1960s that obesity is associated with
ncreased insulin secretion (34), which is not caused by
besity per se—or at least not exclusively—but by the
ccompanying reduced insulin sensitivity.
In the setting of insulin resistance, the secretion of several
dipokines from adipocytes is altered (35). Adiponectin
lasma levels are usually found to be decreased in obese
ndividuals, and the reduction in adiponectin levels may be
elated to insulin resistance (36). Adiponectin, one of the
ost abundant proteins in human fat cells, has insulin-
ensitizing properties (37). Moreover, it has anti-
nflammatory effects on the cellular components of the
essel wall (38), and adiponectin administration lowers
RP and TNF-alpha levels in adiponectin knockout mice
39). A reciprocal association of CRP with adiponectin has
een reported in both human plasma and adipose tissue
40). We asked whether adiponectin levels may predict
hromboxane-dependent platelet activation. Although
bese women had lower SI and adiponectin levels than
ontrols, a multiple regression analysis with 11-dehydro-
XB2 as the dependent variable indicated that only SI and
HR independently predicted 11-dehydro-TXB2 levels.
oreover, impaired SI significantly discriminated subjects
ith higher urinary excretion of 11-dehydro-TXB2 among
hose with android obesity but not among those with gynoid
besity (Fig. 1).
There is increasing evidence that features of the insulin
esistance syndrome, including visceral obesity, are associ-
ted with increased CRP levels (41), suggesting that an
xpanded abdominal fat depot may be responsible for a
ow-grade inflammatory state, by providing a source of
ncreased production of interleukin-6, a stimulus to CRP
ynthesis by the liver. Previously, CRP and CD40L were
ound elevated in healthy women with visceral obesity o9,42). In the present study both inflammatory proteins
ere elevated in obese individuals with insulin resistance;
owever, their relation to increased platelet activation ap-
eared to be largely explained by differences in WHR and
nsulin sensitivity.
Further evidence for a cause-and-effect relationship be-
ween insulin resistance and persistent platelet activation
as obtained through a short-term, diet-induced weight
oss program. This demonstrated that a 10% reduction in
ody weight obtained through a successful program over a
2-week period was associated with a doubling in SI levels
nd normalization of a noninvasive index of platelet activa-
ion. The obese women who failed to achieve a significant
eight loss during this period provided an interesting
ontrol group, which demonstrated the reproducibility of
he relationship between SI levels and 11-dehydro-TXB2
xcretion over time in the presence of relatively constant
ody weight.
Given the concurrent weight loss, one might argue that
eight loss, per se, may modulate platelet function,
ndependently of the improvement in insulin sensitivity.
o avoid this potential confounding, we performed a
ingle-blind, placebo-controlled study with pioglitazone,
n agent known to ameliorate insulin resistance (14,43)
ithout a detectable effect on body weight (or in some
ases with a modest weight gain). A 3-week treatment
ith pioglitazone led to a significant reduction in
hromboxane-dependent platelet activation, with no sig-
ificant change in body weight. This result is consistent
ith recent findings in a mouse model of obesity and
nsulin resistance, where pioglitazone afforded protection
gainst occlusive arterial thrombosis by lowering platelet
-selectin expression (44). Moreover, pioglitazone has no
irect inhibitory effects on agonist-induced platelet ag-
regation (45), suggesting that the reduction in in vivo
latelet activation after pioglitazone described in the
resent study is mediated through improved insulin
ensitivity. As persistent platelet activation in obese
omen is driven by inflammatory triggers (9), we cannot
xclude the possibility that concurrent anti-inflammatory
ffects exerted by pioglitazone may have contributed to
own-regulating platelet activation.
The pathophysiological mechanisms coupling platelet
ctivation with insulin resistance remain elusive. Recently, a
arge body of evidence from cellular, physiological, clinical,
nd epidemiologic studies strongly supports a reciprocal
elationship between insulin resistance and endothelial
unction, raising the hypothesis that endothelial dysfunction
ay provide the missing link between insulin resistance and
latelet activation, thereby connecting disorders of meta-
olic and cardiovascular homeostasis (46).
Several limitations of the intervention studies should be
mphasized. These include self-selection of the participat-
ng women, lack of randomization to weight loss versus
eight maintenance or to pioglitazone versus placebo, lack
f generalizability of the findings to gynoid obese women as
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ize of these pilot studies.
Despite these limitations, these preliminary findings may
ave clinical implications, by supporting the hypothesis that
nsulin resistance, per se, is a major determinant of en-
anced platelet activation in the setting of visceral obesity.
hus, our results suggest that a substantial reduction in
hromboxane-dependent platelet activation in this setting
ay be achieved by increasing insulin sensitivity and provide
rationale for performing adequately sized randomized
tudies comparing the effects of caloric restriction and
nsulin sensitizing agents.
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